

J.P.Morgan

Q4 2025 Medtech Licensing and Venture Report

December 2025

Fueled by

DEALFORMA 



Executive summary

MEDTECH EXITS STRENGTHENED IN 2025, LED BY IPOs AND SUSTAINED M&A ACTIVITY

Medtech exit activity improved through Q4 2025, with both IPO and M&A volumes exceeding full-year 2024 levels. M&A included two headline acquisitions that equated to more than \$41 billion. Public market receptivity increased modestly, allowing a broader set of medtech companies to access U.S. exchanges relative to recent years.

Strategic acquirers remained active, supporting deal flow across company sizes and subsectors. Together, IPOs and M&A continued to provide viable exit paths, contrasting with more constrained conditions across other healthcare verticals.

Here are a few highlights from our Q4 2025 report:

- **Medtech venture activity:** There were 62 venture rounds totaling \$2.0 billion in Q4 2025, bringing the 2025 total to \$11.3 billion across 323 rounds.
- **Medtech licensing partnerships:** There were 20 medtech licensing partnership deals announced in Q4 2025, with only one deal disclosing a total deal value of \$200 million with \$75 million upfront. The 2025 total reached \$10.0 billion, with \$221 million committed upfront.
- **M&A:** 27 medtech M&A deals were announced in Q4 2025, totaling \$43.4 billion in upfront cash and equity, driven by two deals totaling \$41.3 billion.
- **IPOs:** One medtech IPO raised \$314 million on Nasdaq in Q4 2025, bringing 2025 IPO volume to \$1.8 billion across eight offerings of \$15 million+ on U.S. exchanges.

J.P. Morgan is committed to your success. Our relationships, our capital, and our skilled team of bankers and specialists dedicated to the life sciences and healthcare sectors reflect our conviction in the pivotal contributions these clients add to their stakeholders—society, shareholders and employees alike.

Our bankers’ expertise ranges from advising companies at the earliest stage of formation to the most graduated, complex M&A and capital markets transactions. Regardless of the size or stage of your company, we are prepared, equipped and enthusiastic about advising and enabling you to meet your strategic, financial and technical objectives.

Thank you for taking the time to read this report. We look forward to supporting you.

Kathryn McDonough
Head of Life Sciences
Innovation Economy, Commercial Banking
J.P. Morgan

Parameters

Medtech companies are defined as firms developing medical devices, diagnostics, therapeutic digital health and commercial research tools. Healthcare IT and payer/provider software are excluded.

Therapy areas, development stages, modalities and deal structures are segmented per the DealForma database.


Financials are based on disclosed figures curated by DealForma. Multiple tranches of the same Series are counted as one together.

Deals are tracked globally unless otherwise noted.


Data as of December 15, 2025

Medtech venture funding softened in the second half of 2025 after a strong start

QUARTERLY MEDTECH VENTURE INVESTMENT VS. ANNUAL VENTURE DEAL COUNT¹



10-YEAR U.S. TREASURY YIELD VS. MEDTECH VENTURE DEPLOYMENT (INDEXED)^{1,2}




Medtech venture investment entered 2025 at elevated levels, then softened in Q2 and Q3 amid a broader healthcare pullback. Q4 totaled \$2.0 billion, below Q4 2024, reflecting slower deployment and fewer large rounds.

Even with this deceleration, full-year funding was meaningful at \$11.3 billion across 323 rounds, only \$1.3 billion below 2024, indicating continued investor engagement, particularly for differentiated technologies and later-stage companies.


Notes: ¹Financials based on disclosed figures. Data through December 15, 2025. ²Medtech venture capital deployment is indexed to Q1 2020, where Q1 2020 = 100.

Large venture rounds continued to anchor medtech financing in 2025

COUNT OF VENTURE INVESTMENT ROUNDS BY ROUND SIZE¹



COUNT OF R&D LICENSES BY DISCLOSED UPFRONT CASH AMOUNT¹




A notable share of medtech venture capital in 2025 flowed into large rounds, with 61 financings exceeding \$50 million and 30 of those above \$100 million. In aggregate, these transactions raised \$8.0 billion—roughly 71% of medtech venture funding in 2025—and supported scaled platforms and capital-intensive development programs.

Medtech licensing and R&D partnership upfront payments remained limited by comparison as only four deals exceeded \$10 million in disclosed upfront consideration.

Note: ¹Financials based on disclosed figures. Data through December 15, 2025.

Later-stage medtech venture rounds made up nearly two-thirds of all deals

MEDTECH SEED AND SERIES A VENTURE ACTIVITY VS. SERIES B+ VENTURE ACTIVITY¹




Series B and later-stage rounds comprised a majority share of medtech venture activity in 2025, with 210 of 323 financings (65%) and \$9.3 billion in deal value. Capital continued to gravitate to companies with clinical validation, regulatory visibility, or established commercial traction.

Seed and Series A activity was more measured, totaling \$1.9 billion across 113 rounds, reflecting a higher bar for early programs and longer diligence cycles.

Note: ¹Financials based on disclosed figures. Data through December 15, 2025.

U.S. medtech hubs captured majority share of venture capital in 2024-2025

MEDTECH VENTURE INVESTMENT BY GEOGRAPHY, 2024-2025¹




Note: ¹Financials based on disclosed figures. Data through December 15, 2025.

Medtech companies raised \$23.8 billion in venture capital globally in 2024 and 2025. \$16.3 billion of that was invested in U.S.-based companies.

The San Francisco Bay Area biopharma and medtech hub remained the largest by capital raised at \$4.6 billion, followed by Boston/Cambridge. Boston-area medtech companies raised \$2.7 billion, more than doubling prior-year levels and signaling renewed regional momentum. Other established hubs, including San Diego, Philadelphia, and Research Triangle Park, continued to attract targeted investment.

Licensing value concentrated in one mega-deal; upfront share stands at 2%

MEDTECH R&D PARTNERSHIP AND LICENSING DEAL VALUE TOTALS AND UPFRONT CASH AS A PERCENTAGE OF DEAL VALUE¹




2025 medtech licensing deals reached \$10.0 billion in total announced deal value across 89 transactions, with disclosed upfronts totaling \$221 million—just 2% of value. Most of the 2025 medtech licensing nominal value was concentrated in the XtalPi-DoveTree partnership, which includes up to \$5.9 billion in contingent milestones.

Overall, deal structures continued to emphasize regulatory and commercial milestones, reflecting ongoing risk aversion and a preference for contingent economics tied to product performance.


Note: ¹Financials based on disclosed figures. Data through December 15, 2025.

Medtech M&A dominated by two mega-deals in Q4


MEDTECH M&A ACTIVITY^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY^{1,2}



COUNT OF M&A DEALS BY ACQUIRED COMPANY TYPE^{1,2}




Medtech M&A finished 2025 with 27 transactions totaling \$43.4 billion in cash and equity, and full-year deal value reached \$44.6 billion. Headline value was driven by two megadeals—Abbott’s \$23 billion acquisition of Exact Sciences and the \$18.3 billion take-private of Hologic by Blackstone and TPG.

Excluding these transactions, Q4 deal value was \$3.3 billion, highlighting that momentum is real at the top end, but the broader market is selective and quality-driven, favoring assets with clear pathways to scale and cash-flow sustainability.

Note: ¹Financials based on disclosed figures. Data through December 15, 2025. ²Medtech M&A with any buyer type, acquisition options, and reverse mergers.

2025 was the most active medtech IPO market since 2021

MEDTECH IPO ACTIVITY^{1,2}



Medtech IPO activity finished 2025 strong, with eight U.S. offerings over \$15 million raising a combined \$1.8 billion. Q4 was highlighted by BillionToOne’s \$314 million debut, and the year included five additional IPOs above \$100 million.

While the window remains relatively quiet by historical standards, 2025 was the most active year for medtech IPOs since 2021. This increased momentum points to a constructive, if discerning, public market for differentiated medtech platforms with durable growth trajectories.

Note: ¹Financials based on disclosed figures. Data through December 15, 2025. ²includes only NASDAQ and NYSE IPOs \$15 million and larger by completion date.

Chase, J.P. Morgan, JPMorgan, JPMorgan Chase, and Story by J.P. Morgan are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide (collectively, "JPMC", "We", "Our" or "Us", as the context may require). The information in this content (website, article, event invitation or other form) does not represent an offer or commitment to provide any product or service. The views, opinions, analyses, estimates and strategies, as the case may be ("views"), expressed in this content are those of the respective authors and speakers named in those pieces, and/or the JPMC departments that publish the content and may differ from those of JPMorgan Chase Commercial Banking and/or other JPMC employees and affiliates. These views are as of a certain date and often based on current market conditions, and are subject to change without notice. Any examples used are generic, hypothetical and for illustration purposes only. Any prices/quotes/statistics included have been obtained from sources deemed to be reliable, but we do not guarantee their accuracy or completeness. To the extent indices have been used in this content, please note that it is not possible to invest directly in an index. This is not a product of the Research Department of J.P. Morgan Securities LLC. This information in no way constitutes research and should not be treated as such. Any information related to cybersecurity provided is intended to help clients protect themselves from cyber fraud, not to provide a comprehensive list of all types of cyber fraud activities nor to identify all types of cybersecurity best practices.

Copying, re-publishing, or using this material or any of its contents for any other purpose is strictly prohibited without prior written consent from JPMorgan. In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information that was acquired from public sources. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation unless otherwise noted. Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.

The information in this content is not advice on legal, tax, investment, accounting, regulatory, technology or other matters. You should always consult your own financial, legal, tax, accounting or similar advisors before making any financial or investment decisions, or entering into any agreement for JPMC products or services. In no event shall JPMC or any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, the information in this content. We are not acting as your or any client's agent, fiduciary or advisor, including, without limitation, as a Municipal Advisor under the Securities and Exchange Act of 1934. JPMC assumes no responsibility or liability whatsoever to you or any client with respect to such matters, and nothing herein shall amend or override the terms and conditions in the agreement(s) between JPMC and any client or other person.

The information in this content does not include all applicable terms or issues, and is not intended as an offer or solicitation for the purchase or sale of any product or service. Our products and services are subject to applicable laws and regulations, as well as our service terms and policies. Not all products and services are available in all geographic areas or to all customers. In addition, eligibility for particular products and services will be determined by JPMC, including satisfaction of applicable legal, tax, risk, credit and other due diligence, and JPMC's "know your customer", anti-money laundering, anti-terrorism and other policies and procedures. Credit is subject to approval. Rates and programs are subject to change. Certain restrictions apply.

Products and services may be provided by banking affiliates, securities affiliates or other JPMC affiliates or entities. In particular, securities brokerage services other than those that can be provided by banking affiliates will be provided by appropriate registered broker/dealer affiliates, including J.P. Morgan Securities LLC and J.P. Morgan Institutional Investments Inc. Any securities provided or otherwise administered by such brokerage services are not deposits or other obligations of, and are not guaranteed by, any banking affiliate and are not insured by the Federal Deposit Insurance Corporation. Certain financial products and services are required by law to be provided only by licensed representatives and affiliates. Inquiries regarding such products and services will be referred to a licensed representative or a licensed affiliate. The information in this content is not an offer to sell, or solicit an offer to purchase, any securities by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which JPMC or the person making such an offer is not qualified to do so, or to anyone to whom it is unlawful to make such an offer or solicitation, or to anyone in any jurisdiction outside of the United States. Nothing in this content constitutes any commitment by JPMC to underwrite, subscribe for or place any securities, or to extend or arrange credit, or to provide any other product or service. JPMC contact persons may be employees or officers of any JPMC subsidiary or affiliate.

Any information requested on this invitation, page or other relevant registration form will be processed for the purposes of preparation and administration of this event. Providing the requested information will also assist us in ensuring that the event is properly tailored to meet the requirements of the attendees. By providing the information requested, you are consenting to your data being processed by employees and agents of JPMC as well as potential co-organizers for these purposes. You expressly consent to our use of your information in the manner described herein and in our privacy policy (www.jpmorgan.com/privacy).

Please note that any JPMC-hosted event or webinar that you register to attend may be recorded, and videos, photographs and other recordings may be taken, where you may be captured participating in the event. By providing the information requested on the registration form, you consent to the publication of such photographs, videos, recordings and/or likenesses (whether edited, adapted, modified or copied), and their use by us and those that we authorize, without prior notice or compensation, in any way which we may see fit now or in the future, including but not limited to, marketing and advertising. Further, you release JPMC and its employees and agents from all claims of every kind on account of such use. You also acknowledge and agree that the replay links, if any, will be shared with JPMC clients and prospects who were invited but did not register/attend, and also potentially to other third parties if the topics are relevant to them. If you do not agree with any statements in this paragraph, please make a member of our staff aware on the day of the event.

The statements made in this content or during this event, or provided in materials as part of this event, are proprietary to JPMC and are not intended to be legally binding. Any products and services described during these events are offered by JPMC subject to applicable laws and regulations and service terms.

We will provide reasonable accessibility accommodations brought to our attention.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: <https://www.jpmorgan.com/IBOR>.

© 2026 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A., organized under the laws of the U.S.A. with limited liability. Deposits held in non-U.S. branches, are not FDIC insured.